Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for ?6 million on September 20, 2022. The transaction is subject to a number of customary conditions and is anticipated to close in the fourth quarter of this year. Pierre-Olivier Mahieu and Sophie Rutten of Allen & Overy LLP (Brussels) acted as legal advisor to Celyad Oncology SA (ENXTBR:CYAD).
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3 EUR | 0.00% |
|
-2.91% | -23.08% |
04/04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
09/02 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.08% | 13.29M | |
+40.80% | 53.67B | |
+36.02% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA for ?6 million.